← All trials
NCT03879603
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 29, 2019
- Primary completion
- Feb 29, 2020
- Completion date
- Feb 28, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 30
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- BattelleCollaborator
- The EMMES CorporationCollaborator
- National Institutes of Health (NIH)Study chair
- LeidosCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.